Naya Biosciences, INC 8-K filings
INVO Bioscience has entered into an agreement to sell future sales, receiving $225,000 in net proceeds for working capital and general corporate purposes.
8-K: INVO Bioscience Faces Funding Shortfall as NAYA Bioscience Fails to Meet Second Tranche Payment
INVO Bioscience is seeking alternative funding after NAYA Bioscience failed to deliver a $500,000 payment for preferred stock by the agreed deadline.